Existing investors Felicis Ventures and Amplify Partners also joined the round, bringing the total PicnicHealth has raised to more than USD 100m.
The company also announced plans to build 30 new patient-centered real-world data cohorts, and the addition of Adam Seabrook, Partner at B Capital Group, to the PicnicHealth board of directors.
PicnicHealth takes a patient-centered approach to building real-world datasets for life sciences researchers.
This longitudinal data avoids typical gaps in existing real-world data sources by working directly with consented patients, the company said.
All datasets include complete medical records from all of a patient's sites of care and can be supplemented with direct patient-reported experience and linked to other research data sources.
The PicnicHealth Research Platform, since its launch in 2020, has powered the creation of patient-centered real-world data cohorts in hematology (including hemophilia, sickle cell disease, paroxysmal nocturnal hemoglobinuria, and immune thrombocytopenia); neurology (including multiple sclerosis, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, myasthenia gravis, and Huntington's disease); and rare diseases (including lupus nephritis, primary biliary cholangitis, and Pompe disease).
Accordignn to the company, dozens of global life sciences and biopharmaceutical companies rely on these datasets to surface the real-world experiences of more diverse populations than can be studied in clinical trials alone, ultimately getting the right treatments to the right patients faster.
Funds raised will support PicnicHealth in growing its portfolio of patient-centered real-world data cohorts across 30 new indications in complex, chronic, or rare conditions.
The company will also introduce new capabilities to bring this same depth and completeness to aid clinical trial sponsors in linking trial data with longitudinal real-world outcomes.
In addition, PicnicHealth plans enhancements to streamline and speed the patient experience of gaining access to up-to-date medical records.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA